about us

We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in development for MDS and AML. We are also developing ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]

latest news

MEI Pharma Presents at NewsMakers of the Biotech Industry [ Webcast ]

MEI Pharma Reports Fiscal Year 2014 Results [ September 9, 2014 ]

MEI Pharma Completes Enrollment in Randomized Phase II Clinical Trial of Pracinostat in Front Line MDS
[ September 2, 2014 ]

MEI Pharma Reports High Response Rates in Phase II Study of Pracinostat in Front Line AML [ June 10, 2014 ]

MEI Pharma Initiates Clinical Study of Mitochondrial Inhibitor ME-344 in Small Cell Lung and Ovarian Cancers
[ May 5, 2014 ]


Annual Review Cover
Click here for our 2013 Annual Review